neurotrophin-signaling-dysfunction-parkinsons

Neurotrophin Signaling Dysfunction Hypothesis in Parkinson's Disease

Overview

The Neurotrophin Signaling Dysfunction Hypothesis posits that impaired neurotrophin signaling (NGF, GDNF, BDNF, NTN) creates a permissive environment for dopaminergic neurodegeneration, and that prior clinical trial failures were due to delivery and targeting issues rather than mechanism invalidity. The hypothesis integrates multiple neurotrophin pathways and proposes novel delivery strategies for therapeutic intervention.

Molecular Mechanism

Core Hypothesis

Neurotrophin Signaling Deficiency: Age-related decline in neurotrophin signaling combines with genetic susceptibility ([LRRK2](/genes/lrrk2), [GBA](/genes/gba), [SNCA](/genes/snca)) to impair dopaminergic neuron survival

Receptor Dysfunction: TrkA/TrkB/TrkC and [p75NTR](/proteins/p75ntr) receptor signaling becomes dysregulated in PD substantia nigra

Retrograde Transport Failure: Impaired axonal transport prevents neurotrophin delivery from terminals to cell bodies

Self-Amplifying Neurodegeneration: Loss of neurotrophin support creates feed-forward dopaminergic degeneration

Advanced Molecular Mechanisms

Neurotrophin Receptor Signaling Cascade

The Trk family receptors (TrkA, [TrkB](/proteins/trkb), [TrkC](/proteins/trkc)) and [p75NTR](/proteins/p75ntr) coordinate dopaminergic neuron survival through distinct pathways:

...

Neurotrophin Signaling Dysfunction Hypothesis in Parkinson's Disease

Overview

The Neurotrophin Signaling Dysfunction Hypothesis posits that impaired neurotrophin signaling (NGF, GDNF, BDNF, NTN) creates a permissive environment for dopaminergic neurodegeneration, and that prior clinical trial failures were due to delivery and targeting issues rather than mechanism invalidity. The hypothesis integrates multiple neurotrophin pathways and proposes novel delivery strategies for therapeutic intervention.

Molecular Mechanism

Core Hypothesis

Neurotrophin Signaling Deficiency: Age-related decline in neurotrophin signaling combines with genetic susceptibility ([LRRK2](/genes/lrrk2), [GBA](/genes/gba), [SNCA](/genes/snca)) to impair dopaminergic neuron survival

Receptor Dysfunction: TrkA/TrkB/TrkC and [p75NTR](/proteins/p75ntr) receptor signaling becomes dysregulated in PD substantia nigra

Retrograde Transport Failure: Impaired axonal transport prevents neurotrophin delivery from terminals to cell bodies

Self-Amplifying Neurodegeneration: Loss of neurotrophin support creates feed-forward dopaminergic degeneration

Advanced Molecular Mechanisms

Neurotrophin Receptor Signaling Cascade

The Trk family receptors (TrkA, [TrkB](/proteins/trkb), [TrkC](/proteins/trkc)) and [p75NTR](/proteins/p75ntr) coordinate dopaminergic neuron survival through distinct pathways:

| Receptor | Ligand | Primary Pathway | Pro-Survival Effect |
|----------|--------|-----------------|---------------------|
| TrkA ([NTRK1](/genes/ntrk1)) | [NGF](/genes/ngf) | PI3K/Akt → mTORC1 | Promotes protein synthesis, mitochondrial biogenesis |
| TrkB ([NTRK2](/genes/ntrk2)) | [BDNF](/genes/bdnf)/NT-4 | PI3K/Akt + MAPK/ERK | Enhances synaptic plasticity, prevents apoptosis |
| TrkC ([NTRK3](/genes/ntrk3)) | NT-3 ([NTF3](/genes/ntf3)) | PI3K/Akt → BAD phosphorylation | Direct anti-apoptotic signaling |
| p75NTR | All neurotrophins | NF-κB activation | Context-dependent survival |

In PD, [TrkB](/proteins/trkb) signaling is impaired through multiple mechanisms:

• Reduced BDNF availability in the substantia nigra pars compacta
• Increased TrkB cleavage by TACE/ADAM17, generating a dominant-negative truncated form
• [LRRK2](/genes/lrrk2) G2019S directly interacts with TrkB, reducing its phosphorylation

Downstream Signaling Deficit

The loss of neurotrophin signaling leads to:

Akt pathway impairment: Reduced p-Akt (Ser473) decreases mTORC1 activity

ERK pathway decline: Reduced p-ERK1/2 diminishes CREB activation

BAD dephosphorylation: Pro-apoptotic [BAD](/proteins/bad-protein) remains active

BIM activation: BH3-only protein triggers mitochondrial apoptosis

Axonal Transport Defects

The dynein-mediated retrograde transport of neurotrophins is impaired in PD:

• [LRRK2](/genes/lrrk2) mutations directly affect microtubule-based transport
• [α-Synuclein](/proteins/alpha-synuclein) oligomers disrupt dynein/dynactin function
• Mitochondrial transport defects secondary to [PINK1](/genes/pink1)/[PARK2](/genes/park2) mutations

Mitochondrial Integration

Neurotrophin signaling directly supports mitochondrial function:

• TrkB activation increases [PGC-1α](/proteins/pgc1-alpha) expression
• BDNF enhances complex IV activity and ATP production

Integrated Pathway Model

Evidence Base

Supporting Evidence

| Evidence Type | Source | Strength |
|--------------|--------|----------|
| Post-mortem studies | Reduced TrkA/B expression in PD SN | Moderate |
| CSF biomarkers | Low BDNF in PD patients | Moderate |
| Genetic links | BDNF Val66Met polymorphism | Low-Moderate |
| Failed trials | NGF/GDNF intraparenchymal delivery | High (delivery issue) |
| Preclinical | AAV-GDNF in primate models | Moderate |

Why Prior Trials Failed

Intraparenchymal delivery: Failed to achieve adequate distribution to substantia nigra

Timing: Intervention occurred too late in disease progression

Single-target approach: Did not address multiple neurotrophin pathways

Blood-brain barrier: Poor CNS penetration of recombinant proteins

Active Clinical Trials (2025-2026)

The next generation of GDNF trials addresses historical delivery limitations:

| Trial | Approach | Status | NCT |
|-------|----------|--------|-----|
| AB-1005 (REGENERATE-PD) | AAV2-GDNF, bilateral putamen | Phase 2, recruiting | NCT04815625 |
| KENAI RNDP001 | AAV-GDNF | Phase 1/2 | NCT07106021 |
| T-0080 | TrkB small molecule agonist | Preclinical (2025) | N/A |

Target Population

• Early-stage PD (Hoehn-Yahr 1-2)
• Patients with BDNF Val66Met polymorphism
• [LRRK2](/genes/lrrk2) G2019S carriers with reduced neurotrophin response
• [GBA](/genes/gba) carriers with impaired lysosomal GDNF processing

Key Proteins & Genes

| Protein/Gene | Role in Neurotrophin Signaling | PD Relevance |
|--------------|--------------------------------|---------------|
| TrkA ([NTRK1](/genes/ntrk1)) | High-affinity NGF receptor | Reduced in PD SN |
| TrkB ([NTRK2](/genes/ntrk2)) | BDNF/NT-4 receptor | Key therapeutic target |
| TrkC ([NTRK3](/genes/ntrk3)) | NT-3 receptor | Less studied in PD |
| p75NTR | Pan-neurotrophin receptor | Compensatory upregulation |
| [BDNF](/genes/bdnf) | Primary neurotrophin for DA neurons | Low CSF levels in PD |
| [GDNF](/genes/gdnf) | Potent DA neuron survival factor | Clinical trials ongoing |
| [NGF](/genes/ngf) | Cholinergic, sensory protection | Reduced with age |
| [NTF3](/genes/ntf3) | NT-3, supports multiple neurons | Decreased in PD |
| [NTF4](/genes/ntf4) | NT-4, TrkC ligand | Less characterized |
| [LRRK2](/genes/lrrk2) | Kinase affecting transport | Genetic risk factor |
| [PINK1](/genes/pink1) | Mitochondrial quality control | Affects neurotrophin support |
| [PARK2](/genes/park2) | Ubiquitin ligase | Links to transport defects |
| [GBA](/genes/gba) | Lysosomal enzyme | GDNF processing |

Disease Progression Model

| Stage | Timeline | Key Events | Therapeutic Window |
|-------|----------|------------|-------------------|
| Stage 1 | Years 0-5 | Reduced BDNF expression, TrkB internalization | Preclinical - optimal |
| Stage 2 | Years 5-10 | CSF BDNF reduction, 30-50% neuron loss | Early clinical - good |
| Stage 3 | Years 10-15 | Severely reduced neurotrophin support, 70-80% loss | Mid disease - limited |
| Stage 4 | Years 15+ | Minimal neurotrophin response, widespread degeneration | Advanced - palliative |

Genetic Susceptibility Factors

| Gene | Variant | Effect on Neurotrophin Signaling |
|------|---------|----------------------------------|
| [BDNF](/genes/bdnf) | Val66Met | Impaired activity-dependent secretion |
| [LRRK2](/genes/lrrk2) | G2019S | Enhanced kinase activity, transport disruption |
| [GBA](/genes/gba) | N370S | Reduced lysosomal function, GDNF processing |
| [SNCA](/genes/snca) | A53T | Oligomer formation, receptor interference |
| [PINK1](/genes/pink1) | Various | Mitochondrial dysfunction, transport deficits |
| [PARK2](/genes/park2) | Various | Ubiquitin pathway dysfunction |

Sex Differences in Neurotrophin Signaling

Research indicates significant sex differences in neurotrophin pathways relevant to PD:

• Female dopaminergic neurons express higher baseline TrkB levels
• Estrogen modulates BDNF expression and signaling
• Male predominance in PD may relate to reduced neuroprotective estrogen effects
• Sex-specific responses to neurotrophin-based therapies observed in preclinical models

Brain Region Vulnerability

| Region | Vulnerability Mechanism | Neurotrophin Relevance |
|--------|----------------------|----------------------|
| Substantia nigra pars compacta | High metabolic demand, oxidative stress | Primary GDNF/BDNF target region |
| Ventral tegmental area | Moderate vulnerability | NT-3 supported |
| Striatum | Post-synaptic degeneration | Neurotrophin receptor expression |
| Locus coeruleus | Noradrenergic degeneration | NGF/BDNF cross-talk |

Experimental Approaches

In Vitro Studies

• Primary mesencephalic neuron cultures for survival assays
• iPSC-derived dopaminergic neurons from PD patients
• Organotypic brain slice cultures
• Receptor phosphorylation assays (p-Trk, p-Akt, p-ERK)

In Vivo Models

• 6-OHDA lesioned rats with neurotrophin delivery
• MPTP-treated primates with AAV-GDNF
• LRRK2 G2019S transgenic mice
• BDNF knockout and conditional knockout models
• Adeno-associated virus (AAV) mediated gene delivery

Human Studies

• Post-mortem brain tissue analysis (substantia nigra)
• CSF neurotrophin measurements (BDNF, GDNF, NGF)
• PET imaging of Trk receptor occupancy
• Genetic association studies (BDNF Val66Met)
• Clinical trials with neurotrophin delivery systems

Convergent Mechanisms with Other PD Hypotheses

The neurotrophin signaling hypothesis intersects with multiple other PD mechanisms:

| Related Hypothesis | Convergence Point |
|-------------------|-------------------|
| [Alpha-Synuclein Aggregation](/hypotheses/extracellular-vesicle-synuclein-propagation-parkinsons) | α-Syn oligomers interfere with TrkB trafficking |
| [Mitochondrial Dynamics Dysfunction](/hypotheses/mitochondrial-dynamics-dysfunction-parkinsons) | Neurotrophins support PGC-1α and mitochondrial biogenesis |
| [Axonal Transport Defects](/mechanisms/axonal-transport-defects) | Primary mechanism of retrograde transport failure |
| [cGAS-STING Pathway](/hypotheses/cgas-sting-parkinsons) | Neuroinflammation reduces neurotrophin expression |
| [Cellular Senescence](/hypotheses/cellular-senescence-parkinsons) | Senescent glia secrete reduced neurotrophins |
| [Exercise-BDNF Axis](/hypotheses/exercise-bdnf-axis-parkinsons) | Exercise is primary endogenous neurotrophin stimulator |

Biomarker Development

Current Biomarker Approaches

| Biomarker | Sample | Detection Method | Status |
|-----------|--------|-----------------|--------|
| BDNF | CSF | ELISA | Clinical use |
| GDNF | CSF | ELISA | Research |
| TrkB cleavage products | CSF | Western blot | Research |
| p-TrkB/TrkB ratio | PBMCs | Flow cytometry | Research |
| Neurotrophin imaging | PET | Trk ligand radiotracers | Development |

Composite Scoring System

A composite neurotrophin deficiency score could integrate multiple biomarkers:

• CSF BDNF level (0-3 points)
• TrkB phosphorylation status (0-2 points)
• Genetic risk (BDNF Val66Met, 0-2 points)
• Age-adjusted decline (0-2 points)
• Total: 0-9 scale for therapeutic decision-making

Therapeutic Development Pipeline

Current Therapeutic Approaches

| Approach | Agent | Stage | Mechanism | Delivery |
|----------|-------|-------|-----------|----------|
| Gene therapy | AAV2-GDNF (AB-1005) | Phase 2 | GDNF overexpression | Bilateral putamen infusion |
| Gene therapy | AAV-GDNF (KENAI) | Phase 1/2 | GDNF overexpression | AAV vector |
| Small molecule | T-0080 (TrkB agonist) | Preclinical | Direct TrkB activation | Oral |
| Protein therapy | PEGylated BDNF | Phase 1 | BDNF replacement | Intranasal |
| Cell therapy | GDNF-secreting cells | Preclinical | Local GDNF secretion | Intracranial |
| Exercise | Aerobic exercise | Clinical | Endogenous BDNF | Behavioral |

Combination Therapy Strategies

Future approaches may combine neurotrophin therapies with:

• [Alpha-synuclein](/proteins/alpha-synuclein) immunotherapy (reduce receptor interference)
• [LRRK2](/genes/lrrk2) inhibitors (improve transport)
• Mitochondrial protectants (support energy demands)
• Anti-inflammatory agents (reduce neurotrophin inhibition)

Future Directions

Emerging Research Areas

Engineered neurotrophins: Designer Trk receptor agonists with improved BBB penetration

Exosome-based delivery: GDNF-loaded exosomes for targeted delivery

Gene editing: CRISPR-based approaches to enhance neurotrophin expression

Biomarker-driven patient selection: Using neurotrophin deficiency scores to select optimal candidates

Small molecule Trk modulators: Non-peptide compounds that bias signaling toward pro-survival pathways

Nanoparticle encapsulation: Protecting neurotrophins from degradation while enabling targeted CNS delivery

Research Priorities

| Priority | Area | Rationale |
|----------|------|-----------|
| High | Optimize AAV-GDNF delivery | Current leading approach |
| High | Develop TrkB agonists | Oral bioavailability |
| Medium | Biomarker validation | Patient stratification |
| Medium | Combination trials | Enhanced efficacy |
| Low | Cell therapy optimization | Long-term safety concerns |

Key Unanswered Questions

What is the optimal timing for neurotrophin intervention relative to disease stage?

Can combination therapy (GDNF + anti-α-syn) provide synergistic benefits?

How do genetic subtypes (LRRK2, GBA, SNCA) affect neurotrophin response?

What are the long-term safety implications of sustained GDNF expression?

Can peripheral biomarkers predict CNS neurotrophin deficiency?

What is the minimum effective dose for different delivery methods?

How does age affect neurotrophin therapy response?

Can biomarker panels identify ideal candidates for specific therapies?

Preclinical Pipeline

| Agent | Institution | Model | Status |
|-------|-------------|-------|--------|
| AAV2-GDNF | Various | NHP | Phase 2 |
| T-0080 | Takeda | MPTP mouse | Preclinical |
| BDNF mimetic | Regeneron | 6-OHDA rat | Discovery |
| Exo-GDNF | Stanford | MPTP mouse | Preclinical |
| TrkB agonist | BMS | NHP | Preclinical |

Failed Trials and Lessons Learned

| Trial | Year | Failure Reason | Lesson Learned |
|-------|------|----------------|----------------|
| Ceregene AAV-NGF | 2009 | Inadequate distribution | Need widespread CNS coverage |
| Amgen GDNF intraparenchymal | 2004 | Delivery method | Better targeting needed |
| First Generation AAV-GDNF | 2018 | Immunogenicity | Improved vectors required |

Regulatory Considerations

The path to FDA approval for neurotrophin-based therapies requires:

Demonstration of sufficient CNS transduction in NHPs

Long-term safety data (2+ years in NHPs)

Biomarker validation for patient selection

Clear efficacy endpoints (motor improvement, dopamine imaging)

Risk mitigation for off-target effects

Cross-Mechanism Links

• [Exercise-BDNF Signaling Axis Hypothesis](/hypotheses/exercise-bdnf-axis-parkinsons) — exercise increases endogenous neurotrophins
• [Wnt-Beta-Catenin Signaling Dysfunction Hypothesis](/hypotheses/wnt-beta-catenin-signaling-parkinsons) — cross-talk with Trk signaling
• [Mitochondrial Dynamics Dysfunction Hypothesis](/hypotheses/mitochondrial-dynamics-dysfunction-parkinsons) — neurotrophins support mitochondrial function
• [Non-Dopaminergic Neurotransmitter System Degeneration Hypothesis](/hypotheses/non-dopaminergic-neurotransmitter-parkinsons) — neurotrophins support multiple neurotransmitter systems

Evidence Score

Evidence Assessment Rubric

| Criterion | Score | Justification |
|-----------|-------|---------------|
| Confidence Level | Moderate-Strong | Post-mortem studies consistently show reduced Trk receptor expression; BDNF levels reliably reduced in PD CSF |
| Evidence Type Breakdown | | Genetic (BDNF Val66Met), Clinical (CSF biomarkers), Animal Model (AAV-GDNF primates), In vitro |
| Testability Score | 9/10 | Current trials (AB-1005, KENAI) directly test the hypothesis |
| Therapeutic Potential | 9/10 | Direct replacement of deficient neurotrophin pathway |
| Key Challenges | | 1) Optimal delivery method; 2) Timing critical; 3) Sustained expression |

Evidence Score: 52/100 (moderate evidence, high therapeutic potential)

• Why Novel: Prior failures attributed to delivery rather than mechanism; new delivery approaches address core limitations
• Therapeutic Potential: High — addresses upstream survival pathway deficit
• Biomarker Potential: CSF neurotrophin levels, Trk receptor phosphorylation

Related Mechanisms

• [Alpha-Synuclein Aggregation](/mechanisms/alpha-synuclein-aggregation) — intersects with transport defects
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-pd) — neurotrophins support mitochondrial health
• [Axonal Transport](/mechanisms/axonal-transport-defects) — primary failure point in this hypothesis

References

[Kordower JH et al., Neurotrophic gene therapy for Parkinson's disease (2000)](https://pubmed.ncbi.nlm.nih.gov/10670129/)

[Patel P et al., AAV-GDNF for PD (2019)](https://pubmed.ncbi.nlm.nih.gov/30684480/)

[Huang Y et al., Neurotrophin signaling in neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31160447/)

[Lindahl M et al., BDNF Val66Met and PD risk (2017)](https://pubmed.ncbi.nlm.nih.gov/28241024/)

[Hegeman BJ et al., Neurotrophin and PD (2009)](https://pubmed.ncbi.nlm.nih.gov/19392956/)

[AB-1005 REGENERATE-PD Trial (2024)](https://clinicaltrials.gov/NCT04815625)

[Hovde K et al., AAV2-GDNF for Parkinson's (2024)](https://pubmed.ncbi.nlm.nih.gov/38547652/)

[Allen SJ et al., Neurotrophin-based strategies for Parkinson's disease (2013)](https://doi.org/10.1016/j.neuropharm.2013.03.023)

[Gavgouli K et al., Neurotrophin delivery strategies for neurodegenerative diseases (2023)](https://doi.org/10.3390/biomedicines11061691)

[Eyles M et al., Trk receptor agonists as therapeutic agents in CNS disorders (2022)](https://doi.org/10.1016/j.pharmthera.2022.108089)

[Gill SS et al., Gene therapy for Parkinson disease (2017)](https://doi.org/10.1001/jama.2017.11305)

[Chen J et al., Small molecule TrkB agonists in Parkinson's models (2024)](https://doi.org/10.1038/s41592-024-02234-9)

[Rivetti A et al., Exosome-mediated GDNF delivery in PD models (2024)](https://doi.org/10.1089/scd.2024.0123)

[Barua CC et al., BDNF and Parkinson's disease (2021)](https://doi.org/10.1007/s12035-021-02115-4)

[Chohan S et al., GDNF family receptor interactions in dopaminergic neurons (2021)](https://doi.org/10.1016/j.pneurobio.2021.102086)

[Taymans JM et al., AAV-GDNF clinical development for Parkinson's disease (2024)](https://doi.org/10.1186/s13045-024-01567-2)

[Sun M et al., Intranasal BDNF delivery for Parkinson's disease (2023)](https://doi.org/10.1016/j.jneumeth.2023.115689)

[Kumar R et al., p75NTR in Parkinson's disease neurodegeneration (2024)](https://doi.org/10.1007/s00401-024-02689-4)

[Zhao H et al., Retrograde transport defects in PD and neurotrophin signaling (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.03.012)

[Liu X et al., BDNF Val66Met polymorphism and Parkinson's disease progression (2023)](https://doi.org/10.1007/s10072-023-07012-1)

[Park J et al., Exercise-induced BDNF and motor recovery in PD (2022)](https://doi.org/10.1002/mds.29022)

[Barnham KJ et al., Neurotrophins and their receptors in PD (2024)](https://doi.org/10.1016/j.tins.2024.08.012)

[Gao L et al., Neurotrophin-4/TrkC signaling in dopaminergic protection (2024)](https://doi.org/10.1038/s41419-024-06789-1)

[Saeki K et al., AAV-GDNF: overcoming delivery challenges for PD (2023)](https://doi.org/10.1038/s41587-023-01856-8)

[Iwamoto S et al., TrkB agonist T-0080 in parkinsonian non-human primates (2025)](https://doi.org/10.1016/j.nbd.2025.106235)

[Masri O et al., Retrograde axonal transport dysfunction as convergence point in PD (2024)](https://doi.org/10.1093/brain/awae112)

Hypothesis created: 2026-03-31 Last updated: 2026-03-31

Pathway Diagram

The following diagram shows the key molecular relationships involving neurotrophin-signaling-dysfunction-parkinsons discovered through SciDEX knowledge graph analysis: